Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Research Report 2024
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
According to Mr Accuracy reports’s new survey, global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market is projected to reach US$ 2791.2 million in 2034, increasing from US$ 2066 million in 2024, with the CAGR of 4.3% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market research.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.
North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market is projected to reach US$ 2791.2 million in 2034, increasing from US$ 2066 million in 2024, with the CAGR of 4.3% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market research.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.
North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices